Amarin’s Vascepa gets priority review for cardiovascular label expansionAmarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results Share XAmarin’s Vascepa gets priority review for cardiovascular label expansionhttps://pharmaphorum.com/news/amarins-vascepa-gets-priority-review-for-cardiovascular-label-expansion/
